2L
MACK

22NW LP’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

22NW LP’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,015,048
Closed -$11.6M – 20
2022
Q4 		$11.6M Sell
1,015,048
-215,966
-18% -$1.78M 6.28% 6
2022
Q3 		$4.62M Sell
1,231,014
-10,882
-0.9% -$50.2K 2.61% 17
2022
Q2 		$7.39M Hold
1,241,896
– – 3.92% 11
2022
Q1 		$7.86M Hold
1,241,896
– – 2.85% 15
2021
Q4 		$4.86M Hold
1,241,896
– – 1.5% 22
2021
Q3 		$6M Hold
1,241,896
– – 1.79% 22
2021
Q2 		$7.94M Hold
1,241,896
– – 2.13% 19
2021
Q1 		$7.8M Hold
1,241,896
– – 2.4% 19
2020
Q4 		$8.56M Hold
1,241,896
– – 3.06% 15
2020
Q3 		$4.97M Hold
1,241,896
– – 2.52% 18
2020
Q2 		$4.14M Hold
1,241,896
– – 2.24% 14
2020
Q1 		$2.67M Hold
1,241,896
– – 2.08% 12
2019
Q4 		$3.91M Hold
1,241,896
– – 4.44% 11
2019
Q3 		$5.59M Sell
1,241,896
-336,554
-21% -$1.68M 7.37% 4
2019
Q2 		$7.51M Buy
1,578,450
+190,184
+14% +$901K 8.14% 3
2019
Q1 		$7.59M Buy
1,388,266
+435,903
+46% +$2M 5.29% 5
2018
Q4 		$2.89M Buy
+952,363
New +$3.3M 1.8% 23

Other funds holding MACK

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Sepio Capital Salt Lake City, Utah $1.84B AUM 18.57% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return

22NW LP's MACK Position: Q1 2023 in Review

22NW LP sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2023, closing a stake of 1,015,048 shares — an estimated $11.6M sold.

22NW LP first reported a position in MACK in Q4 2018 and held it in 17 quarters. The position peaked at $11.6M in Q4 2022. 50 funds tracked by Wall St. Rank hold MACK as of Q1 2023.

  • 22NW LP reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • 22NW LP sold 1,015,048 Merrimack Pharmaceuticals, Inc. shares in Q1 2023, an estimated $11.6M.
  • 22NW LP first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2018 and held it in 17 quarters.
  • 22NW LP's Merrimack Pharmaceuticals, Inc. position peaked at $11.6M in Q4 2022.
  • 50 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2023.

Based on 22NW LP's 13F filing for Q1 2023, filed 15 May 2023.